Literature DB >> 445962

Cephalothin kinetics: before, during, and after cardiopulmonary bypass surgery.

K W Miller, K K Chan, H G McCoy, R P Fischer, W G Lindsay, D E Zaske.   

Abstract

Cephalothin kinetics was studied in 5 patients the day before (PREOP), during (SURG), and the day after (POSTOP) cardiopulmonary bypass surgery. The PREOP (114 ml/min) and SURG (94 ml/min) renal clearances were of the same order but both were less than POSTOP renal clearance (248 ml/min). Cephalothin total body clearance during operation was lower (p less than 0.01) than PREOP or POSTOP clearance, with decreased metabolic clearance the primary cause. There was reduction in cephalothin elimination throughout the surgical procedure, not only in the period of extracorporeal circulation, indicating that general anesthesia had a significant influence on drug disposition. The metabolite deacetylcephalothin was rapidly formed on all 3 days and its kinetic behavior paralleled that of the parent drug.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 445962     DOI: 10.1002/cpt197926154

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

1.  Prospective, open-label investigation of the pharmacokinetics of daptomycin during cardiopulmonary bypass surgery.

Authors:  Megan H Nguyen; Samantha J Eells; Jennifer Tan; Corinne T Sheth; Bassam Omari; Margarita Flores; Jeffrey Wang; Loren G Miller
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

2.  Effects of cardiopulmonary bypass surgery on intravenous ciprofloxacin disposition.

Authors:  R D Pryka; K A Rodvold; W Ting; S Levitsky; R W Frost; J T Lettieri
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 3.  Effect of cardiopulmonary bypass on the pharmacokinetics of drugs.

Authors:  F O Holley; K V Ponganis; D R Stanski
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of the non-depolarising muscle relaxants.

Authors:  M I Ramzan; A A Somogyi; J S Walker; C A Shanks; E J Triggs
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

5.  Alcuronium kinetics in patients undergoing cardiopulmonary bypass surgery.

Authors:  J S Walker; K F Brown; C A Shanks
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

6.  The effect of cardiopulmonary bypass on plasma protein binding of alfentanil.

Authors:  K Kumar; D P Crankshaw; D J Morgan; G H Beemer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  Ceftriaxone disposition in open-heart surgery patients.

Authors:  G L Jungbluth; M T Pasko; T R Beam; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

8.  Pharmacodynamics of fentanyl citrate in patients undergoing aortocoronary bypass.

Authors:  Adolph J Koska; Alexander Romagnoli; William G. Kramer
Journal:  Cardiovasc Dis       Date:  1981-09

Review 9.  Cardiopulmonary bypass and the pharmacokinetics of drugs. An update.

Authors:  W A Buylaert; L L Herregods; E P Mortier; M G Bogaert
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

10.  Effect of cardiopulmonary bypass on vancomycin and netilmicin disposition.

Authors:  K J Klamerus; K A Rodvold; N A Silverman; S Levitsky
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.